ライフサイエンスコーパス: PDT

1 PDT (660-nm light) was carried out against S. mutans bio

2 PDT as an exclusive therapy may be considered a non-inva

3 PDT percutaneous dilatational tracheostomy was subsequen

4 PDT was applied with verteporfin at a dose of 6 mg/m(2)

5 PDT-sensitive cells expressed higher Mfrn2 mRNA and prot

6 ed sites randomly received the following: 1) PDT; 2) photosensitizer (PS); or 3) scaling and root pla

7 The 5th and 10th PDT-resistant cells showed an amplicon in 5q11.2 MAP3K1,

8 by repeated MAL-PDT treatments (5th and 10th PDT-resistant generations).

9 In group B (n = 175), PDT percutaneous dilatational tracheostomy was performed

10 ration of a combination of type 1 and type 2 PDT ROS in organic- and aqueous-based solutions.

11 showed that all derivatives would be type 2 PDT-active, and ROS-activated fluorescent probes were us

12 cy of bacteria inactivation, we conjugated a PDT photosensitizer, cationic or neutral porphyrin, to a

13 ling and root planing (SRP) alone (group A), PDT followed by SRP (group B), or KTP laser followed by

14 d cycle of curettage and aminolevulinic acid PDT with resolution.

15 treated with curettage + aminolevulinic acid PDT.

16 ed curettage followed by aminolevulinic acid PDT.

17 In addition, PDT protocol presented inferior frequency of P. gingival

18 ment in BCVA at months 1, 3, 6, and 12 after PDT (P < .05 for all times).

19 an tumor xenografts, compared with 16% after PDT-alone.

20 umor xenografts immediately before and after PDT at different time points.

21 omography (OCT), and recurrence of CSC after PDT were compared between the 2 groups.

22 visual outcome and recurrence of CSCR after PDT were identified with multivariate regression analysi

23 .2 +/- 113 mum; P = 0.005) and 30 days after PDT (362.3 +/- 111 mum; P = 0.002).

24 d choroidal thickness may persist even after PDT.

25 easures were changes in choroidal maps after PDT (mean +/- SD) and the relationship between choroidal

26 At 36 months after PDT, 132 eyes (97.1%) achieved complete resolution of SR

27 lete resolution of SRF within 6 months after PDT, but 3 eyes that received half-dose PDT had persiste

28 d >/=3 lines of BCVA loss at 36 months after PDT.

29 d recurrence rate of CSCR at 36 months after PDT.

30 Antitumor immunity is stimulated after PDT because of the acute inflammatory response that invo

31 The mean follow-up time after PDT was 14.8 +/- 13.3 months.

32 n PpIX fluorescence and cell viability after PDT.

33 had little effect on PpIX production and ALA-PDT in normal and ER- or HER2-positive cells.

34 the on-going development of image-guided ALA-PDT treatment technologies for global health application

35 activity renders TNBC cell resistance to ALA-PDT and inhibiting ABCG2 transporter is a promising appr

36 fluorescence were the most sensitive to ALA-PDT and TNBC cells with the lowest PpIX level were resis

37 umulation and sensitized cancer cells to ALA-PDT.

38 t that PAGs may be an attractive alternative PDT modality to selectively induce cell death in oxygen-

39 Although PDT has been used primarily as an anti-cancer therapy, t

40 Although PDT potentiated irinotecan treatment, we also demonstrat

41 Measuring and monitoring intrinsic and PDT-induced tumor hypoxia in vivo during PDT is of high

42 herapy with the combination of anti-VEGF and PDT in eyes that have failed anti-VEGF monotherapy resul

43 es had complete SRF resolution after another PDT treatment.

44 Escherichia coli for potential antimicrobial PDT (aPDT) applications.

45 he selectivity and efficiency of 5-ALA based PDT in cancer therapy.

46 ng recent developments of nanoparticle-based PDT agents, their combinations with different drugs, des

47 at the anti-tumor effects of photofrin based PDT was strongly augmented by miR-99a overexpression and

48 otinib is administered in three doses before PDT of H460 human tumor xenografts, compared with 16% af

49 -duration administration of erlotinib before PDT can greatly improve the responsiveness of even erlot

50 uding subretinal fluid, were recorded before PDT and during follow-up examinations.

51 75 nm irradiation); and Group 5, rose bengal PDT (rose bengal + 518 nm irradiation).

52 D viability imaging revealed synergy between PDT and the standard-of-care chemotherapeutic carboplati

53 agent and immunogenic cell death induced by PDT.

54 llowing induction of sterile inflammation by PDT.

55 late transporter 4, which was upregulated by PDT.

56 ly viewed as the starting point for clinical PDT in modern medicine.

57 ic index and extend the spectrum of clinical PDT far beyond what was imagined when that sentinel manu

58 describe a treatment strategy that combines PDT by a new chlorin-based nanoscale metal-organic frame

59 th low oxygen tension is known to compromise PDT.

60 ting energy transfer-based (1) O2 controlled PDT.

61 Yet to date, PDT efficacy has been mostly characterized using 2D cult

62 ry/release, near-infrared (NIR)-excited deep PDT, and radiosensitization, respectively, all of which

63 ted against several dermatological diseases (PDT) and (antibiotic-resistant) pathogenic microorganism

64 a were recruited; 35 eyes received half-dose PDT and 26 eyes received half-time PDT.

65 ic CSCR are recommended to undergo half-dose PDT before they have significant visual deterioration.

66 ients with chronic CSCR undergoing half-dose PDT between 2005 and 2011 were reviewed.

67 Chronic CSCR patients treated with half-dose PDT can achieve long-term stable visual acuity and resol

68 rences in the half-fluence PDT and half-dose PDT groups, respectively (P = .07).

69 fter PDT, but 3 eyes that received half-dose PDT had persistent SRF before loss to follow-up at month

70 Half-dose PDT induced a more rapid reabsorption of the fluid, a mo

71 28 patients (29 eyes) who received half-dose PDT.

72 y to develop CSCR recurrence after half-dose PDT.

73 onstrate that combination of single low-dose PDT and a subclinical dose of nanoliposomal irinotecan s

74 Our results demonstrate that low-dose PDT can promote osteoblast differentiation via the activ

75 rimary mesenchymal stromal cells to low-dose PDT.

76 The use of US guidance before and during PDT percutaneous dilatational tracheostomy could render

77 t of ALA-induced PpIX in cancer cells during PDT.

78 aptive modification of light delivery during PDT on a fine scale to optimize treatment response.

79 urate quantification of tumor hypoxia during PDT.

80 and PDT-induced tumor hypoxia in vivo during PDT is of high interest for prognostic and treatment eva

81 easing the level of GSH for highly efficient PDT.

82 sitizer-MnO2 nanosystem for highly efficient PDT.

83 We believe that nMOF-enabled PDT has the potential to significantly enhance checkpoin

84 osomal iron release to the cytosol, enhanced PDT-induced cell killing of both resistant and sensitive

85 equently, DBP-UiO displayed greatly enhanced PDT efficacy both in vitro and in vivo, leading to compl

86 ese results may indicate relatively enhanced PDT response by AFXL pretreatment in diseased skin.

87 MOF nanoparticle formulation showed enhanced PDT efficacy with superior (1) O2 control compared to th

88 However, the efficiency of existing PDT drug molecules in the deep-tissue-penetrable near-in

89 d pain associated with microneedle expedited PDT.

90 median 6.5 versus 4.3 months, P<0.01), fewer PDT treatments needed (median 1 versus 3, P<0.01), a hig

91 patients (31 eyes) who received half-fluence PDT and 28 patients (29 eyes) who received half-dose PDT

92 ere 15 and 5 recurrences in the half-fluence PDT and half-dose PDT groups, respectively (P = .07).

93 nd 30 days after treatment with half-fluence PDT.

94 nd equal safety with respect to half-fluence PDT.

95 ntional photosensitisers used clinically for PDT are ineffective for photochemical internalisation ow

96 summarizes the attributes of BODIPY dyes for PDT, and in some related areas.

97 exceptionally effective photosensitizer for PDT of resistant head and neck cancer.

98 rious microfluidic Lab-on-a-chip systems for PDT efficacy analysis on 3D culture and discusses micros

99 Normal fluence was used for PDT treatment in 130 treatments (49%), half-fluence was

100 Half-dose and half-time FA-guided PDT were both effective and safe in treating CSC and sho

101 , which ensured its effective imaging-guided PDT.

102 However, PDT-induced tumor hypoxia as a result of oxygen consumpt

103 3 transformed TiO2 from a dual type I and II PDT agent to a predominantly type I photosensitizer, irr

104 We have designed a new Ru(II) PDT candidate that efficiently enters cells by incorpora

105 sign of new (1)O2 donors and applications in PDT.

106 s a potential means of the (1) O2 control in PDT.

107 therapy agents, no significant difference in PDT was observed.

108 proving the possibility of ROS generation in PDT/SDT.

109 A statistically significant improvement in PDT mediated efficacy (p<0.001) was also observed when t

110 Efficacy research has been neglected in PDT for a long time.

111 key requirement for the generation of ROS in PDT and given the fact that hypoxia is a characteristic

112 anotechnology-based photosensitizers used in PDT.

113 market and clinical trials that are used in PDT/PDI.

114 2 ](+) or [Ru(bpy)3 ](2+) moieties to induce PDT by generating reactive oxygen species (ROS).

115 al iron uptake act synergistically to induce PDT-mediated and iron-dependent mitochondrial dysfunctio

116 ns new avenues of particle expansion-induced PDT enhancement by controlled imidazole chemistry.

117 gy between oxaliplatin and pyrolipid-induced PDT kills tumour cells and provokes an immune response,

118 o killing of cancer cells in DBC-UiO-induced PDT.

119 Patient demographic information, PDT treatment parameters, fluorescein angiographic infor

120 PCV, number or type of anti-VEGF injections, PDT therapy, or baseline choroidal thickness.

121 T with methyl-delta-aminolevulinic acid (MAL-PDT) and the tumors acquire an infiltrative phenotype an

122 an biopsies from persistent tumors after MAL-PDT.

123 istant SCC-13 cells obtained by repeated MAL-PDT treatments (5th and 10th PDT-resistant generations).

124 Rose bengal-mediated PDT successfully inhibited the growth of 3 types of fung

125 Rose bengal-mediated PDT successfully inhibited the growth of all 3 fungal is

126 findings indicate that nanoparticle-mediated PDT can potentiate the systemic efficacy of checkpoint b

127 PpIX-mediated PDT monotherapy induced cell death in a dose-dependent m

128 mental groups, including riboflavin-mediated PDT, had any inhibitory effect on the isolates.

129 There were no PDT-related complications.

130 antiangiogenic treatment and vaso-occlusive PDT.

131 randomization, 71.6% (95% CI, 60.8-82.4) of PDT patients and 91.4% (95% CI, 85.3-97.5) of 0.5-mg pat

132 In patients with CP, a single application of PDT (using a 638-nm laser and toluidine blue) did not pr

133 gen greatly hinders the broad application of PDT as a first-line cancer treatment option.

134 further treatment or a single application of PDT using a 638-nm laser and toluidine blue.

135 technology to extend the clinical benefit of PDT to regions with little or no access to electricity o

136 otivated by the well-established capacity of PDT photosensitizers to serve as tumour-selective fluore

137 tinib increases the in vitro cytotoxicity of PDT to endothelial cells.

138 ctors now viewed as critical determinates of PDT dose, efficacy, and toxicity, that study showed rema

139 An analysis of the effectiveness of PDT compared with other treatments may help physicians d

140 .OBJECTIVE To determine the effectiveness of PDT for the treatment of AKs relative to other methods.D

141 cancer cells through the combined effects of PDT and locally released PTX.

142 cancer cells through the combined effects of PDT and site-specific PTX chemotherapy.

143 ls that provide evidence for the efficacy of PDT in common mental health disorders.

144 th erlotinib augments multiple mechanisms of PDT effect that collectively lead to large improvements

145 The number of PDT treatments was 1 in 89%, 2 in 7%, and 3 in 3% of eye

146 tumors were treated with a single session of PDT, 11 tumors received 2 sessions, 1 tumor received 3 s

147 This review describes the current status of PDT investigations using microfluidic Lab-on-a-Chip syst

148 on levels for the development and testing of PDT agents.

149 pportunities for the clinical translation of PDT and irinotecan combination therapy for effective pan

150 ing criteria: randomised controlled trial of PDT; use of treatment manuals or manual-like guidelines;

151 ed further development and clinical usage of PDT.

152 patient and a hindrance to widespread use of PDT as standard field therapy for AK.

153 ficacy and summarise the evidence for use of PDT to treat mental health disorders.

154 surveyed to retrospectively collect data on PDT treatment for CSC.

155 greatly enhanced the efficacies of RT and/or PDT.

156 g or more and 25 mmHg or more versus sham or PDT.

157 20/40 than patients given sham treatment or PDT.

158 y underscores the potential of metal-organic PDT as an alternate treatment strategy for challenging e

159 We carried out PDT using benzoporphyrin derivative and 690-nm light aft

160 of temoporfin-PDT (T-PDT) is twice that of P-PDT.

161 ts of T-PDT compared with previous data on P-PDT.

162 Photodynamic therapy using porfimer (P-PDT) improves palliation and survival in nonresectable h

163 Compared to previous P-PDT, T-PDT shows prolonged time to local tumor progressi

164 vival time, and similar palliation as with P-PDT.

165 ent of photodynamic therapy photosensitizer (PDT) efficacy on Escherichia coli.

166 Post-PDT follow-up ranged from 1 month to more than 1 year.

167 Post-PDT VA was correlated with baseline VA (r = 0.70, P < 0.

168 mediated by IYIY-I2-BODIPY in pre- and post-PDT conditions.

169 tinal fluid resolved in 81% by the last post-PDT visit.

170 thus represent a new class of highly potent PDT agents and hold great promise in treating resistant

171 20 nm, 100 J/cm(2), 160 mW/cm(2)) to produce PDT effects (drug-light interval 1 h), IYIY-I2-BODIPY in

172 t of PS administration can limit progressive PDT applications.

173 nsition metal complexes are highly promising PDT agents due to intense visible light absorption, yet

174 Since its publication, PDT has been increasingly utilized in clinical practice

175 use models further demonstrate that ZnP@pyro PDT treatment combined with anti-PD-L1 results in the er

176 earch string.STUDY SELECTION Only randomized PDT trials that used aminolevulinic acid hydrochloride o

177 cytokines when isolated from mice receiving PDT of P815 tumors than P1.204 tumors and CD8 T cells fr

178 voltage stability specifically over relevant PDT dose parameters.

179 w depths of tissue penetration that restrict PDT to superficial lesions, inability to treat hypoxic t

180 18 nm irradiation alone; Group 4, riboflavin PDT (riboflavin + 375 nm irradiation); and Group 5, rose

181 ieved complete resolution of SRD with single PDT and 4 eyes (2.9%) had CSCR recurrence.

182 serous retinal detachment (SRD) with single PDT, change in best-corrected visual acuities (BCVAs), a

183 ur observations demonstrate that TP solution PDT have an ameliorating effect on the RA by decreasing

184 o have been treated using SRP alone or SRP + PDT.

185 are robust enough to maintain submicromolar PDT in pigmented metastatic melanoma cells, where the pr

186 For successful PDT of solid tumors, it is necessary to ensure tumor-sel

187 orated by several meta-analyses that suggest PDT is as efficacious as treatments established in effic

188 cacy, survival time, and adverse events of T-PDT compared with previous data on P-PDT.

189 cidal penetration depth of temoporfin-PDT (T-PDT) is twice that of P-PDT.

190 Compared to previous P-PDT, T-PDT shows prolonged time to local tumor progression (med

191 e hilar bile duct cancer were treated with T-PDT (median 1 [range 1-4] sessions) plus stenting and fo

192 ficance of this PS for mitochondria targeted PDT applications in deep tissue cancer therapy.

193 tionic TPyPz derivative in vascular-targeted PDT.

194 Temoporfin-PDT can safely be delivered to hilar bile duct cancer pa

195 Tumoricidal penetration depth of temoporfin-PDT (T-PDT) is twice that of P-PDT.

196 nolide, 2-deoxyglucose, temsirolimus (termed PDT) regimen is a potent means of targeting AML stem cel

197 Taken together, these findings show that PDT can induce a potent antigen- and epitope-specific im

198 Moreover, we show that PDT inhibited survivin expression.

199 Multiple regression analysis showed that PDT type was not correlated with visual improvement (P >

200 The PDT was well tolerated.

201 TNF-alpha was significantly improved in the PDT + SRP versus SRP group.

202 r actinomycetemcomitans were observed in the PDT and SRP protocols at 3 months when compared with the

203 Porphyromonas gingivalis was observed in the PDT protocol at 3 and 6 months and in the SRP protocol a

204 Only patients in the PDT protocol exhibited augmented levels of anti-inflamma

205 asurements of light and dark toxicity of the PDT agents and that the platform allows simultaneous mea

206 The amounts of ROS produced depends on the PDT dose and the nature of the photosensitizer.

207 The preliminary results suggest that the PDT can be an attractive alternative cancer therapy, whi

208 les show superior tumor-targeted therapeutic PDT effects against cancer cells both in vitro and in vi

209 ve bio-imaging and photodynamic therapeutic (PDT) agent for RA theranostics.

210 y substrate for Photo-/Sono-dynamic Therapy (PDT/SDT), hypoxia is also problematic for the treatment

211 by aminolevulinic acid photodynamic therapy (PDT) 1 to 2 weeks later.

212 blue - MB) to mediate photodynamic therapy (PDT) against Streptococcus mutans biofilms.

213 w great promise as new photodynamic therapy (PDT) agents.

214 d for use as potential photodynamic therapy (PDT) agents.

215 to the progression of photodynamic therapy (PDT) and microbial photodynamic inactivation (PDI) in cl

216 he combined effects of photodynamic therapy (PDT) and released chemotherapy drug, without any sign of

217 l peptides (CAMPs) and photodynamic therapy (PDT) are attractive tools to combat infectious diseases

218 ressing the effects of photodynamic therapy (PDT) as an adjunct to conventional scaling and root plan

219 stigates the effect of photodynamic therapy (PDT) as monotherapy during supportive periodontal therap

220 Photodynamic therapy (PDT) can destroy local tumors and minimize normal tissue

221 dition of erlotinib to photodynamic therapy (PDT) can improve treatment response in typically erlotin

222 Photodynamic therapy (PDT) efficacy is limited by the very short half-life and

223 significantly enhanced photodynamic therapy (PDT) efficacy on two colon cancer mouse models as a resu

224 it could be shown that photodynamic therapy (PDT) elevates antitumor immune responses.

225 chemotherapy drugs and photodynamic therapy (PDT) for ovarian cancer.

226 Photodynamic therapy (PDT) has been applied in cancer treatment by utilizing r

227 In recent years photodynamic therapy (PDT) has received widespread attention in cancer treatme

228 s photosensitizers for photodynamic therapy (PDT) in P-glycoprotein (P-gp) expressing cells.

229 s and the discovery of photodynamic therapy (PDT) in the early 1900s, the landmark article in 1978 in

230 Photodynamic therapy (PDT) involves the intravenous administration of photosen

231 Photodynamic therapy (PDT) is a clinically approved anti-cancer treatment that

232 Photodynamic therapy (PDT) is a light-based treatment modality that has exhibi

233 Photodynamic therapy (PDT) is a new strategy for treating local cancers using

234 Photodynamic therapy (PDT) is a promising treatment strategy where activation

235 Photodynamic therapy (PDT) is an alternative treatment for cancer that involve

236 Photodynamic therapy (PDT) is an effective and cosmetically favorable treatmen

237 Photodynamic therapy (PDT) is an effective anticancer procedure that relies on

238 Photodynamic therapy (PDT) is an efficacious treatment for some types of cance

239 Photodynamic therapy (PDT) is an important cancer treatment modality due to it

240 Photodynamic therapy (PDT) is used extensively to treat actinic keratoses(AKs)

241 Photodynamic therapy (PDT) is widely used to treat diverse diseases, but its d

242 Photodynamic therapy (PDT) is widely used to treat non-melanoma skin cancer.

243 edge that the dominant photodynamic therapy (PDT) mechanism of 1a (WST09) switched from type 2 to typ

244 glet oxygen sensitized photodynamic therapy (PDT) relies on the concentration of oxygen in the tissue

245 Although photodynamic therapy (PDT) takes advantage of the spatial-temporal control of

246 delivery of selective photodynamic therapy (PDT) to the cancerous tissues, with minimal harm to the

247 , immunogenic ZnP@pyro photodynamic therapy (PDT) treatment sensitizes tumors to checkpoint inhibitio

248 t harnesses sub-lethal photodynamic therapy (PDT) using a photosensitiser that localises in endolysos

249 acy of photofrin based photodynamic therapy (PDT) was enhanced by miR-99a transfection in human gliob

250 n and cell response to photodynamic therapy (PDT) were analyzed in MCF10A normal breast epithelial ce

251 cence imaging (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and

252 Photodynamic therapy (PDT) with protoporphyrin IX (PpIX), which is endogenousl

253 hyrin derivative-based photodynamic therapy (PDT), a photochemical cytotoxic modality that activates

254 gical diseases through photodynamic therapy (PDT), and advanced materials for engineering molecular a

255 In photodynamic therapy (PDT), cells are impregnated with a photosensitizing agen

256 of porphyrin-mediated photodynamic therapy (PDT), including low depths of tissue penetration that re

257 s laser irradiation or photodynamic therapy (PDT), may provide some additional benefit in the treatme

258 nt tool (chemotherapy, photodynamic therapy (PDT), radiotherapy (RT)) by controlled drug delivery/rel

259 In the case of photodynamic therapy (PDT), two-photon absorption combined with active targeti

260 ers by cancer cells in photodynamic therapy (PDT), we designed a smart plasma membrane-activatable po

261 Photodynamic therapy (PDT), wherein light sensitive non-toxic agents are local

262 s an important role in photodynamic therapy (PDT).

263 tential application in photodynamic therapy (PDT).

264 to singlet oxygen for photodynamic therapy (PDT).

265 osensitizers (PSs) for photodynamic therapy (PDT).

266 d this is the basis of photodynamic therapy (PDT).

267 (PPIX) accumulation in photodynamic therapy (PDT).

268 of great interest for photodynamic therapy (PDT).

269 (2PLM) and two-photon photodynamic therapy (PDT).

270 ships for their use in photodynamic therapy (PDT).

271 ctive chemotherapy and photodynamic therapy (PDT).

272 s, and sensitizers for photodynamic therapy (PDT); and more recently as models for aromaticity (both

273 Psychodynamic therapy (PDT) is an umbrella concept for treatments that operate

274 All eyes that received half-time PDT showed complete resolution of SRF within 6 months af

275 half-dose PDT and 26 eyes received half-time PDT.

276 n delivery to tumours, achieve deeper tissue PDT via red-shifted porphyrin Q-bands, energy transfer a

277 benefit is found when erlotinib is added to PDT of A549 NCSLC xenografts.

278 carcinoma (SCC) do not respond adequately to PDT with methyl-delta-aminolevulinic acid (MAL-PDT) and

279 erent responses in 2D and 3D cell culture to PDT.

280 lly accounts for the benefit of erlotinib to PDT.

281 observed when Colo-26 cells were exposed to PDT and treatment with the cancer drug doxorubicin.

282 correlation of light and drug parameters to PDT-induced tumor response.

283 mice bearing the same tumours 20min prior to PDT treatment.

284 ght eyes (5.9%) had complications related to PDT.

285 tial factors implicated in SCC resistance to PDT, we have used the SCC-13 cell line (parental) and re

286 with the lowest PpIX level were resistant to PDT.

287 t difference in tumor hypoxia in response to PDT over time was found between the U87MG and MDA-MB-435

288 There was no difference in the response to PDT when analyzed by age, race, fluence setting, fluores

289 the development of the resistance of SCC to PDT.

290 Unfortunately, PDT is often followed by recurrence due to incomplete ab

291 rous tumours, treating hypoxic tumours using PDT can be a challenge.

292 IYIY-I2-BODIPY alone and in combination with PDT modulates the immune response in such a way that tum

293 Mfrn2 mRNA and protein levels compared with PDT-resistant cells.

294 R-targeting therapeutics in conjunction with PDT.

295 therapy, but lose potential vision gain with PDT.

296 ients with choroidal metastasis treated with PDT at a single institution were reviewed.

297 demonstrated EPDS successfully treated with PDT.

298 d with cryotherapy and 2170 AKs treated with PDT.

299 MOLs (ca. 1.2 nm) enable highly effective X-PDT to afford superb anticancer efficacy.

300 ons in X-ray-induced photodynamic therapy (X-PDT) of colon cancer.